from TetraKit Technologies
March 16, 2023
Our Chief Scientific Officer, Matthias Herth, is attending the 18th European Molecular Imaging Meeting #EMIM2023 this week in Salzburg, Austria.
As one of the major events in molecular imaging, EMIM brings together experts from various disciplines to share their latest research findings and network with peers.
We are proud to have Dr. Herth represent Tetrakit Technologies at this important event.
Follow us for more updates on our work in molecular imaging!
March 16, 2023
We are proud to announce that Tetrakit Technologies has officially joined the prestigious Venture House at BioInnovation Institute! 🏢🔬
This is a significant milestone for our team, and we couldn’t be happier to be part of such an inspiring ecosystem of innovative biotech and life sciences startups. 🌐
A big thank you to the entire Tetrakit team for their relentless passion, dedication, and hard work that has led us to this incredible opportunity. 🙌
We also want to express our gratitude to the BioInnovation Institute for recognizing our potential and providing us with this exceptional platform to grow, collaborate, and make a lasting impact in the world of biotechnology. 🧪💡
As we embark on this new journey, we’re more motivated than ever to push boundaries, develop groundbreaking solutions, and, ultimately, improve the lives of millions around the globe. 🌍💊
Stay tuned for more updates on our progress and the exciting developments to come! 🚀Read more
March 15, 2023
A warm welcome to our newest team member, Nadia. With experience in organic and biomolecular chemistry, Nadia brings knowledge and expertise to our team. Nadia is part of our collaboration with the University of Copenhagen for the development of theranostics targeting the neuropeptide Y1 receptor.
Sure, I graduated from the Technical University of Denmark with an MSc in Applied Chemistry. Through my previous project, I obtained key competencies in biomolecular design, synthesis, characterization, and planning and running bioassays. I am highly motivated to work with biomolecular chemistry because of the urgent need and high applicability in modern diagnostics and medicine.
TetraKit develops unique radiolabeling based on click chemistry to facilitate cancer diagnosis and therapy. I am happy to be part of the TetraKit team during my Ph.D. fellowship, as I see my research profile fitting within these objectives. Especially, I am excited to be working with a talented team and contributing to further developing the TetraKit solutions. In my new role, I look forward to expanding my expertise working with radiopharmaceutical chemistry, which will allow me to utilize my skills in the development of theranostics.
As a Ph.D. fellow, I wish to expand my scientific profile and conduct high-level research. This role is ideal for me to do so. The skills and experience I gain in this role will give me a unique set of professional skills of high value for my future carrier.
We are thrilled to have Nadia on board and look forward to this cooperation. Welcome to the team, Nadia!Read more
Chief Executive Officer
“Targeted radionuclide therapy has been demonstrated to be very effective in oncology. However, a practical and universal labeling platform has thus far not been developed. TetraKit Technologies will develop such a platform. We expect that this platform will bring more powerful treatments to patients, especially with advanced metastatic cancer.”
Chief Scientific Officer
“TetraKit Technologies does not only provide a new platform enabling kit-labeling of almost any targeting vector with any radionuclide, but will also apply this technology to develop NextGen Theranostics based on the theranostic radionuclide pair fluoride-18 and astatine-211.”